secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001628280-26-016516
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda CEO reveals NEREUS launch plan: DTC channel, availability in months
-------------------------------------------------------------------------

- NEREUS approved by FDA for prevention of vomiting induced by motion sickness.
- CEO disclosed development of direct-to-consumer channel NEREUSRX for NEREUS access.
- NEREUS will be available in the next couple of months per CEO on Fox Business.
- Pricing and commercial strategy for NEREUS discussed during interview.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026016516/0001628280-26-016516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026016516/vnda-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-016516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer